SecBot SecBot
6-K ·Filed Jul 30, 2026

GSK

GSK plc
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0001654954-26-007005
Actionable Insight • Neutral

No actionable trading signal. This is a routine PDMR share sale disclosure with no bearing on GSK's fundamentals. Monitor for any cluster of insider sales or changes in executive shareholding patterns in future filings.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$52.07
T+0 close · Jul 30, 2026 · via day close
Latest settled
−2.54%
T+60 · $50.75
Vs SPY
−5.00%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 30 $52.07entry
  2. T+1 · 4mo ago −0.73%α −1.44% · $51.69
  3. T+5 · 3mo ago +0.19%α −3.43% · $52.17
  4. T+20 · 3mo ago −3.46%α −7.42% · $50.27
  5. T+60 · 25d ago −2.54%α −5.00% · $50.75
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GSK filed a routine 6-K disclosing that President of Global Supply Chain Regis Simard sold 38,000 ordinary shares at £20.38 on July 29, 2026. The sale is a single PDMR transaction with no material financial impact on the company. This filing is administrative in nature and does not signal any change in GSK's business operations or financial health.

Key Facts

  • President of Global Supply Chain Regis Simard sold 38,000 ordinary shares on July 29, 2026
  • Sale price was £20.38 per share
  • Transaction executed on the London Stock Exchange (XLON)
  • Filing is a standard PDMR transaction notification under UK rules

Financial Impact

Sale of 38,000 shares at £20.38 totals approximately £774,440, immaterial relative to GSK's $107.8B market cap

Risk Factors

  • No material risks identified from this filing

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
43% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (GSK), Batch item 10001654954-26-007005
Document: 0001654954-26-007005-index-headers.html0001654954-26-007005
Document: 0001654954-26-007005-index.html0001654954-26-007005
Document: 0001654954-26-007005.txt0001654954-26-007005
6-K Filing (GSK), Batch item 50001654954-26-007005
Document: 0001654954-26-007005-index-headers.html0001654954-26-007005
Document: 0001654954-26-007005-index.html0001654954-26-007005
Document: 0001654954-26-007005.txt0001654954-26-007005

US Market Status

Market Closed · Opens Wed (10h 31m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 30, 2026